Login to Your Account



Clinic Roundup


Friday, July 26, 2013

Adaptimmune Ltd., of Oxford, UK, opened a Phase I/IIa, multiple-site, two-cohort, open-label trial in ovarian cancer at Roswell Park Cancer Institute in Buffalo, N.Y., and City of Hope in Duarte, Calif. Researchers will investigate the safety, bioactivity and effectiveness of treating patients with their own T cells after genetically engineering the cells to enhance their antitumor properties.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription